Skip to main content
Quantum Biopharma Ltd. logo

Quantum Biopharma Ltd. — Investor Relations & Filings

Ticker · QNTM ISIN · CA74764Y2050 US Manufacturing
Open in API
Filings indexed 339 across all filing types
Latest filing 2026-06-02 Regulatory Filings
Country US United States of America
Listing US QNTM

About Quantum Biopharma Ltd.

https://www.quantumbiopharma.com/

Quantum Biopharma Ltd. is a biopharmaceutical company developing a portfolio of assets for neurodegenerative, neuropsychiatric, and inflammatory disorders. The company's lead pharmaceutical candidate is Lucid-MS, a patented, first-in-class neuroprotective compound for Multiple Sclerosis that targets myelin repair and has completed Phase 1 human clinical trials. Alongside its drug development pipeline, Quantum Biopharma is launching unbuzzd™, a functional beverage designed to support mental alertness and detoxification following alcohol consumption. The company's dual strategy focuses on both advanced pharmaceutical research and development and consumer wellness products.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 85% confidence The document is a Form 6-K filed with the U.S. SEC by a foreign private issuer, providing a corporate update press release as an exhibit. It is a regulatory submission and does not contain substantive financial statements or constitute a full report itself. Therefore, it falls under the general regulatory filings category (RNS).
2026-06-02 English
FORM 6-K
Regulatory Filings Classification · 80% confidence The document is a U.S. SEC Form 6-K report of a foreign private issuer, transmitting a press release as Exhibit 99.1. It does not itself present financial statements or interim/annual results, nor detail management or governance changes, dividends, or other specific categories. It is a regulatory submission under the Exchange Act. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-06-02 English
FORM 6-K
Regulatory Filings Classification · 88% confidence The document is a Form 6-K filing by a foreign private issuer to furnish a press release under SEC rules. It does not itself contain financial statements or management discussion, but is a general regulatory submission (Form 6-K) with an attached Exhibit. This fits the fallback category for general regulatory announcements, i.e., Regulatory Filings (RNS).
2026-05-18 English
6-K - Quantum Biopharma Ltd. (0001771885) (Filer)
Regulatory Filings Classification · 80% confidence The document is a Form 6-K, which is a SEC regulatory submission by a foreign private issuer to furnish a press release (Exhibit 99.1). It contains no substantive financial data or detailed report content; instead, it simply files a press release as required under SEC rules. This fits the “Regulatory Filings” category (RNS) as it’s a general compliance filing that does not fall under any more specific report type.
2026-05-07 English
6-K - Quantum Biopharma Ltd. (0001771885) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release as Exhibit 99.1 dated April 22, 2026. The text does not contain any substantive financial data or detailed report content but rather references the press release attached as an exhibit. The document length is only 2728 characters, which is quite short and consistent with a regulatory filing or announcement rather than a full report. According to the rules, such filings that provide a press release or report as an attachment or reference without the full report content should be classified as Regulatory Filings (RNS).
2026-04-22 English
6-K - Quantum Biopharma Ltd. (0001771885) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release as Exhibit 99.1 dated April 2, 2026. The text does not contain any financial statements or detailed financial data, but rather references the press release. The document length is 2712 characters, which is relatively short and consistent with an announcement or regulatory filing rather than a full report. Form 6-K filings typically serve as regulatory filings to disclose material information between annual reports. Therefore, this document fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not contain the full report or detailed financial data itself.
2026-04-02 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.